A LIPOPEPTIDE-BASED αVβ3 INTEGRIN-TARGETED ULTRASOUND CONTRAST AGENT FOR MOLECULAR IMAGING OF TUMOR ANGIOGENESIS

The design and fabrication of targeted ultrasound contrast agents are key factors in the success of ultrasound molecular imaging applications. Here, we introduce a transformable alpha v beta(3) integrin-targeted microbubble (MB) by incorporation of iRGD-lipopeptides into the MB membrane for non-invasive ultrasound imaging of tumor angiogenesis. First, the iRGD-lipopeptides were synthesized by conjugating iRGD peptides to distearoyl-phosphatidylethanolamine-polyethylene glycol 2000-maleimide. The resulting iRGD-lipopeptides were used for fabrication of the iRGD-carrying alpha v beta(3) integrin-targeted MBs (iRGD-MBs). The binding specificity of iRGDMBs for endothelial cells was found to be significantly stronger than that of control MBs (p < 0.01) under in vitro static and dynamic conditions. The binding of iRGD-MBs on the endothelial cells was competed off by pre-incubation with the anti-alpha v or anti-beta(3) antibody (p < 0.01). Ultrasound images taken of mice bearing 4T1 breast tumors after intravenous injections of iRGD-MBs or control MBs revealed strong contrast enhancement within the tumors from iRGD-MBs but not from the control MBs; the mean acoustic signal intensity was 10.71 +/- 2.75 intensity units for iRGD-MBs versus 1.13 +/- 0.18 intensity units for the control MBs (p, 0.01). The presence of alpha v beta(3) integrin was confirmed by immunofluorescence staining. These data indicate that iRGD-MBs can be used as an ultrasound imaging probe for the non-invasive molecular imaging of tumor angiogenesis, and may have further implications for ultrasound image-guided tumor targeting drug delivery. (E-mail: lmeihong@fimmu.com or hr.zheng@siat.ac.cn) (C) 2015 World Federation for Ultrasound in Medicine & Biology.